Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Core Therapeutic Areas
> Technology platforms
Priority geographies
Capital allocation / structure
Our priorities
Conclusion
Abbreviations
Building the industry-leading RLT platform
Established leadership in RLT, category creator and
positioned as the go-to partner for collaborations
Robust manufacturing delivering safety and quality
■ 4 manufacturing facilities: Ivrea (Italy), Milburn (US),
Zaragoza (Spain) & Indianapolis (US, opening 2023)
At scale manufacturing & "just-in-time" production/delivery
On track for additional non-carrier added isotope production
Strong commercial execution
with >500 centers and >16,000 patients treated
Leading with the science
▪ 4 ongoing registrational studies
(next readout PSMAfore Q4'22)
■ 8 dedicated early discovery projects
Selected compound (indication)
Lutathera (1L GEP-NET)
Lutathera (Pediatrics + PPGL)1
Lutathera (GBM)²
Lutathera (ES-SCLC)²
Pluvicto (mHSPC)
Pluvicto (mCRPC)
225AC-PSMA-617
(PCa+bone metastases)
NeoB (multi tumor)
1. PPGL, is an exploratory cohort of NETTER-P 2. Phase 1/2
12
Novartis Investor Presentation | September 22, 2022
2. Technology platforms - RLT
Phase 1
Phase 2
Phase 3
U |
NOVARTIS | Reimagining MedicineView entire presentation